The Institute for Biotechnology and Medicine Industry (IBMI/生策會), established in 1996, marks its 30th anniversary this year with a significant strategic pivot. In the recently elected 8th Board of Directors, a notable shift has occurred: while the organization was historically dominated by pharmaceutical executives, the new board now features prominent leaders from the technology and financial sectors, with only two seats held by traditional biotech industry representatives.

Strategic Evolution:

• Financial Integration: COO Alan Wu indicated that IBMI aims to fill critical gaps in the industry by potentially providing a financial investment platform. This follows the success of its sister organization, the Research Center for Biotechnology and Medicine Policy (RBMP), in catalyzing the EverBright Biofund (永明生技投資).
• Bridging Discovery to Market: With Taiwan’s annual science and technology budget reaching NT$160 billion, IBMI is prioritizing the "landing" of research. The board now includes university presidents and medical school deans to facilitate the transition of basic research into commercial applications.
• Policy Outlook: Following President Lai Ching-te’s inauguration anniversary last May, the government’s clear endorsement of biotech policy is viewed as a positive signal for redirecting capital from AI and semiconductors back into the life sciences.

Resource: 生策會提供投資平台 助力生技業